BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.benzinga_article·56 minutes agoBYSI+22.33%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·2 hours agoBYSI+22.33%OMER+29.25%
BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipelinePUBT·Jul 9 at 01:18 PMBYSI+22.33%
BeyondSpring files Form 3 for CFO Na Li showing no beneficial ownershipPUBT·Jul 6 at 12:09 PMBYSI+22.33%
BeyondSpring amends filing to disclose CEO Min Qiu pay package, including USD 100,000 salaryPUBT·Jun 29 at 03:31 PMBYSI+22.33%
BeyondSpring appoints Min Qiu as CEO and Na Li as CFO; Lan Huang to remain as ChairTradingView·Jun 4 at 06:33 AMBYSI+22.33%
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026Unusual Whales·Mar 30 at 06:32 AMSBIO-1.08%BYSI+22.33%
BeyondSpring Files 2025 Annual Report on Form 10-KUnusual Whales·Mar 25 at 03:31 PMFBT-0.91%PBE+0.38%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Mar 3 at 11:05 AMCALC+6.95%IXJ-0.16%
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference | BYSI Stock NewsStockTitan·Feb 8 at 10:15 PMPBE+0.38%IBB-0.74%
